Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.

By S. Robins, D. Collins, J. Wittes, V. Papademetriou, P. Deedwania, E. Schaefer, J. Mcnamara, M. Kashyap, J. Hershman, L. Wexler and 1 more. Journal of the American Medical Association (JAMA), 2001

962 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pharmacology, Surgery

View Paper: https://www.semanticscholar.org/paper/b44e94a19f1e6a1dae20c290c443e847ef2384e6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Peter Libby
2. G. Hansson
3. P. Ridker
4. J. Chapman
5. A. Kontush
6. L. Melvin
7. A. Lichtman
8. I. Tabas

In Pharmacology

1. G. Hansson
2. Peter Libby

In Surgery

1. Peter Libby
2. G. Hansson
3. P. Ridker
4. J. Chapman
5. A. Kontush
6. I. Tabas
7. L. Melvin
8. Jongsoon Lee

Citations in the corpus

• Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis (2006, background): “…during lipolysis, and of HL, which facilitates conversion of large to small HDL. Interestingly, plasma levels of small HDL3-C were a powerful predictor of CV risk in insulin-resistant subjects in the VA-HIT trial involving gemfibrozil treatment in insulin-resistant subjects (Robins et al., 2001).”
• Progress and challenges in translating the biology of atherosclerosis (2011, background): “Clinical trials of one agent with PPAR-α-stimulating activity, gemfibrozil, have shown a reduction in cardiovascular event”
• Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). (2002, background): “Because fibrates have additional nonlipid effects (eg, on inflammatory and thrombotic processes) that affect the development of atherosclerotic lesions and the occurrence of clinical events, it is not unexpected that medicationrelated changes in lipid levels only partially explain clinical efficacy.”